

## REFERRAL CRITERIA

### **Patients are suitable for SABR for lung metastases if they have:**

- 1-3 sites of metastatic disease, which can be treated with stereotactic radiotherapy to a radical radiation dose
- No single metastasis larger than 5cm
- Reasonable performance status (ideally 2 or better)
- Expected life expectancy > six months
- No history of pulmonary fibrosis/interstitial lung disease

### **Please note:**

- Other systemic anti-cancer therapy may need to be omitted before and after SABR delivery, depending on the agent. Hormonal therapy for breast and prostate cancers is permitted
- Patients with central metastases (within 2cm of the proximal bronchial tree) can be considered for SABR

### **Patients require:**

- Up to date (within last 4 weeks) CT imaging of the chest and abdomen (PET-CT can be considered if appropriate)
- Pulmonary Function Tests, including transfer factor